Wall Street analyst estimates for ACADIA Pharmaceuticals Inc. (ACAD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.21 | ||
| 2026-08-04 | $0.18 | $0.07 | +164.1% |
| 2026-05-06 | $0.02 | $0.04 | -50.0% |
| 2026-02-25 | $1.60 | $0.14 | +1067.9% |
| 2025-11-05 | $0.42 | $0.14 | +200.0% |
| 2025-08-06 | $0.16 | $0.14 | +14.3% |
| 2025-05-07 | $0.11 | $0.10 | +10.0% |
| 2025-02-26 | $0.86 | $0.19 | +352.6% |
Valuation Ratios
| P/E Ratio | 12.10 |
| Price / Book | 3.57 |
| EV / EBITDA | 37.93 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.3M | $124.9M | $223.8M | $339.1M | $441.8M | $484.1M | $517.2M | $726.4M | $957.8M | $1.07B |
| Cost of Revenue | $4.4M | $13.1M | $18.3M | $19.6M | $20.6M | $19.1M | $10.2M | $45.7M | $81.8M | $89.0M |
| Gross Profit | $12.9M | $111.8M | $205.5M | $319.5M | $421.2M | $465.0M | $507.1M | $680.7M | $876.0M | $982.5M |
| Research & Development | $99.3M | $149.2M | $187.2M | $240.4M | $319.1M | $239.4M | $361.6M | $351.6M | $303.2M | $328.8M |
| Selling, General & Admin | $186.5M | $255.1M | $265.8M | $325.6M | $388.7M | $396.0M | $369.1M | $402.5M | $488.4M | $548.9M |
| Operating Expenses | $285.7M | $404.3M | $452.9M | $566.0M | $707.8M | $635.4M | $730.7M | $754.1M | $645.2M | $877.7M |
| Operating Income | -$272.8M | -$292.4M | -$247.4M | -$246.5M | -$286.6M | -$170.4M | -$223.6M | -$73.4M | $230.8M | $104.8M |
| EBITDA | -$271.0M | -$289.7M | -$244.4M | -$243.8M | -$283.7M | -$164.2M | -$211.4M | -$45.5M | $100.2M | $150.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$270.1M | -$288.3M | -$243.9M | -$234.4M | -$281.0M | -$167.5M | -$213.4M | -$51.0M | $258.1M | $138.9M |
| Income Tax | $1.3M | $1.1M | $1.3M | $876000 | $611000 | $351000 | $2.5M | $10.2M | $31.6M | -$252.1M |
| Net Income | -$271.4M | -$289.4M | -$245.2M | -$235.3M | -$281.6M | -$167.9M | -$216.0M | -$61.3M | $226.5M | $391.0M |
| EPS | $-2.34 | $-2.36 | $-1.94 | $-1.60 | $-1.79 | $-1.05 | $-1.34 | $-0.37 | $1.37 | $2.32 |
| EPS (Diluted) | $-2.34 | $-2.36 | $-1.94 | $-1.60 | $-1.79 | $-1.05 | $-1.34 | $-0.37 | $1.36 | $2.29 |
| Shares Outstanding (Diluted) | $115.9M | $122.6M | $126.6M | $147.2M | $157.3M | $160.5M | $161.7M | $163.8M | $166.4M | $171.4M |
Price
| Price | $27.83 |
| Market Cap | $4.8B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADMA · BLTE · CRNX · DYN · IMVT · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of ACAD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks